Jan Skvarka Biography and Net Worth

Jan is an Executive Chairman at DEM Biopharma, and a member of the Board of Directors at Monte Rosa Therapeutics (Nasdaq:GLUE). Previously, he was the CEO of Trillium Therapeutics (Nasdaq:TRIL), a clinical stage immuno-oncology company, where he led a highly successful, 360-degree turn-around that produced a leading CD47 drug candidate, while taking the company from a $16M valuation to a $2.3B buy-out by Pfizer in two years. Prior to that, Jan was the CEO of Tal Medical, a private, clinical stage neuroscience company; a partner in the life sciences practice at Bain & Company, Boston; and a manager at Price Waterhouse Corporate Finance in London, UK and Vienna, Austria. He holds a PhD in economics from the University of Economics in Slovakia, and an MBA from Harvard Business School. Jan qualifies as an “independent” director in accordance with the listing requirements of Nasdaq.

What is Jan Skvarka's net worth?: The estimated net worth of Jan Skvarka is at least $625.12 thousand as of January 31st, 2025. Mr. Skvarka owns 149,551 shares of Zentalis Pharmaceuticals stock worth more than $625,123 as of May 7th. This net worth evaluation does not reflect any other assets that Mr. Skvarka may own. Learn More about Jan Skvarka's net worth.
How do I contact Jan Skvarka?: The corporate mailing address for Mr. Skvarka and other Zentalis Pharmaceuticals executives is 530 SEVENTH AVENUE SUITE 2201, NEW YORK NY, 10018. Zentalis Pharmaceuticals can also be reached via phone at 212-433-3791 and via email at [email protected]. Learn More on Jan Skvarka's contact information.
Has Jan Skvarka been buying or selling shares of Zentalis Pharmaceuticals?: Jan Skvarka has not been actively trading shares of Zentalis Pharmaceuticals over the course of the past ninety days. Most recently, on Friday, January 31st, Jan Skvarka bought 60,000 shares of Zentalis Pharmaceuticals stock. The stock was acquired at an average cost of $1.72 per share, with a total value of $103,200.00. Following the completion of the transaction, the director now directly owns 149,551 shares of the company's stock, valued at $257,227.72. Learn More on Jan Skvarka's trading history.
Who are Zentalis Pharmaceuticals' active insiders?: Zentalis Pharmaceuticals' insider roster includes Kimberly Blackwell (Director), Ingmar Bruns (Chief Medical Officer), Kevin Bunker (COO), Melissa Epperly (CFO), Cam Gallagher (Director), David Johnson (Director), Alexis Pinto (Insider), Jan Skvarka (Director), Anthony Sun (CEO), and Dimitris Voliotis (SVP). Learn More on Zentalis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Zentalis Pharmaceuticals?: In the last twelve months, Zentalis Pharmaceuticals insiders bought shares 1 times. They purchased a total of 6,459,973 shares worth more than $7,751,967.60. In the last twelve months, insiders at the sold shares 8 times. They sold a total of 7,546,617 shares worth more than $10,088,416.65. The most recent insider tranaction occured on February, 10th when insider Vincent Vultaggio sold 6,894 shares worth more than $16,683.48. Insiders at Zentalis Pharmaceuticals own 1.9% of the company. Learn More about insider trades at Zentalis Pharmaceuticals.
Information on this page was last updated on 2/10/2026.

Jan Skvarka Insider Trading History at Zentalis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/31/2025	Buy	60,000	$1.72	$103,200.00	149,551
9/11/2023	Sell	5,000	$25.05	$125,250.00	47,970

Jan Skvarka Buying and Selling Activity at Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Company Overview

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

Today's Range

Now: $4.16

$4.11

$4.18

50 Day Range

MA: $3.25

$2.10

$6.61

2 Week Range

Now: $4.16

$1.13

$6.95

Volume

31,761 shs

Average Volume

1,997,524 shs

Market Capitalization

$295.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.99